UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 10, 2022
(Exact Name of Registrant as Specified in Its Charter)
(Commission File Number)
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(I.R.S. Employer Identification No.)
|
(Address of principal executive offices, including zip code)
(215 ) 619-3200
(Registrant’s telephone number, including area code)
NOT APPLICABLE
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter):
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On January 10, 2022, STRATA Skin Sciences, Inc. (the
“Company”) issued a press release announcing preliminary, unaudited results of operations for the fourth fiscal quarter of 2021. The full text of such press
release is furnished as Exhibit 99.1 to this report.
The information set forth under this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
Item 7.01. Regulation FD Disclosure.
On January 10, 2022, STRATA Skin Sciences, Inc. (the “Company”) issued a press release announcing its preliminary unaudited
results of operations for the fourth fiscal quarter of 2021. The full text of such press release is furnished as Exhibit 99.1 to this report.
On January 10, 2022, Strata Skin Sciences (the
“Company”) posted an investor presentation to its website at https://strataskinsciencesinc.gcs-web.com/. A copy of the investor presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for
the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation
S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation
language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following press release is furnished as an exhibit to this Current Report on Form 8-K pursuant to Item 2.02 and shall not be
deemed to be “filed”:
|
Exhibit No.
|
Exhibit Description
|
|
99.1
|
|
|
99.2
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
- 2 -
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
STRATA SKIN SCIENCES, INC.
|
|
|
|
|
|
|
|
|
Date: January 10, 2022
|
By:
|
/s/ Christopher Lesovitz
|
|
|
|
|
Christopher Lesovitz
|
|
|
|
|
Chief Financial Officer
|
|
- 3 -
EXHIBIT 99.1
STRATA Skin Sciences Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results
Horsham, Pa, January 10, 2022 —STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment
of dermatologic conditions, today reported preliminary,
unaudited fourth quarter 2021 financial results.
Fourth Quarter and Full Year 2021 Financial Highlights
|
•
|
Preliminary, unaudited total revenue is expected to range from $8.8 million to $9.2 million, compared to $6.7 million in the fourth
quarter of 2020
|
|
•
|
Preliminary, unaudited total revenue for the full year 2021 is expected to range from $29.7 million to $30.1 million, compared to $23.1
million for the full year 2020
|
|
•
|
Cash and cash equivalents, including restricted cash was $12.5 million as of December 31, 2021, as compared to $18.1 million as of
December 31, 2020
|
Fourth Quarter 2021 Operational Highlights
|
•
|
Placed 34 domestic XTRAC systems, resulting in net systems placed in U.S. dermatologists’ offices of 890, of which 18 are comebacks
from previous excimer device owners.
|
|
•
|
Increased international partner XTRAC clinics to 54, up from 28 in 2020 and 10 in 2019
|
|
•
|
Converted 17 Pharos systems acquired from Ra Medical’s U.S. dermatology business to STRATA’s recurring revenue model
|
|
•
|
Hired Christopher Lesovitz as CFO
|
“We were pleased with the strong results our team delivered through the fourth quarter of 2021, which were bolstered by favorable year-end
insurance claims and strong commercial execution by the entire STRATA team. Despite headwinds from the Delta and Omicron variants, STRATA continued to make meaningful progress on our strategic initiatives, which were reflected in the quality of our
preliminary financial results,” said Robert Moccia, President & CEO of STRATA Skin Sciences. “Subsequent to year end, we were also delighted to complete the acquisition of Theravant Corporation's acne treatment device assets, enabling us to
enter the $5.5 billion U.S. acne care market. The acquisition represents STRATA's second strategic asset purchase in six months, both of which were executed under new leadership and further establish STRATA’s position as the global leader of
clinical dermatology devices,” concluded Moccia.
The preliminary unaudited results described in this press release are estimates and are subject to revision until the company reports its full
financial results for the year ended December 2021, which is anticipated in mid-March.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products
for the in-office treatment of dermatologic conditions. Its products include the XTRAC® and Pharos® excimer lasers and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.
The Company’s proprietary XTRAC and recently acquired Pharos excimer lasers deliver a highly targeted therapeutic beam of UVB light to treat
psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. The technology is covered by multiple patents.
STRATA’s unique business model in the U.S. leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its
in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include
but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and
sell an acne treatment device and to integrate that device into its product offerings, the Company’s ability to develop, launch and sell products to be developed in the future, the Company’s ability to develop social media marketing campaigns,
and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ
materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions or supply chain interruptions resulting from the coronavirus and political factors or conditions affecting
the Company and the medical device industry in general, future responses to and effects of COVID-19 pandemic and its variants including the distribution and effectiveness of the COVID-19 vaccines, as well as more specific risks and uncertainties
set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this
press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this
press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact
|
Jack Droogan
|
|
|
|
(203) 585-4140
|
|
|
|
ir@strataskin.com
|
- 2 -
Investor Presentation December
2020 Investor
Presentation January 2022 Driving Value to Dermatology Partners Matching Patients with Clinics
Safe Harbor Statement This presentation includes "forward-looking statements" within the meaning of the
Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future
events or trends. These statements, the Company’s ability to migrate customers from the Pharos system to XTRAC® and to execute new service agreements to at least portions of the Pharos user base, to generate the growth in its core business,
including transitioning capital equipment purchasers into recurring revenue users, to integrate the Pharos service business into the Company’s field service offering, the Company’s ability to develop social media marketing campaigns, and the
Company’s ability to build a leading franchise in dermatology, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the
Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions or supply chain interruptions resulting from the coronavirus and political factors or conditions affecting the Company and
the medical device industry in general, future responses to and effects of the COVID-19 pandemic and its variants including the distribution and effectiveness of the COVID-19 vaccines, as well as more specific risks and uncertainties set forth
in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this presentation are made as of the date of this
presentation, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this
presentation. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com. 2
3 Source: 1 Market Data Forecast Report 2021, Fortune Business Insights 2018, 2019 Addressing
large markets for chronic skin diseases with differentiated laser-based treatments Recurring revenue model drives repeat and sustainable revenues Customer base of ~1K partner practices and growing Sales driven by expanding device usage &
new partner practices Expanding international presence in key markets Recent product acquisition opening significant growth opportunity
Positioned for Growth Acceleration in the Treatment of Chronic Skin Conditions 4 CEOCFOVP
MarketingVP of Professional RelationsDirector of Business Operations2 new Board Members (Chairman & Head of Audit Committee) New Leadership Commercial Focus and Execution Acquisitions DTC marketing analyticsDirect to dermatologist
marketingPartnering with advocacy groupsSales training and focusInternational organic growth and expansion Pharos excimer laser business from Ra Medical Systems, Aug ‘21Theraclear acne business from Theravant, January 2022Pipeline of new
indications
Executive Management Team: 100+ yrs. dermatology experience Robert (Bob) J. Moccia, CEO Encore
Dermatology, Precision Dermatology, Medicis Pharmaceuticals, Graceway Pharmaceuticals, Bioglan Pharmaceuticals, Stiefel Laboratories, Dermik Laboratories (RPR) Chris Lesovitz, CFO Encore Dermatology, Iroko Pharmaceuticals Shmuel Gov, VP of
Operations, General Manager, Carlsbad PhotoMedex, U.S.R. Electronic Systems Ltd., Galor Ltd.: Negevtech Inc, Orbotech Inc. (a KLA company) Brent Cowgill, VP Marketing Encore Dermatology, Vantage Marketing Group, Graceway Pharmaceuticals,
Bristol Myers Squibb Keith Simeone, VP Sales VP Sales PhotoMedex Inc.: Sales Director, ForTec Medical Jay Sturm, General Counsel Mela Sciences, Volcano Capital LLC, GC Vital Signs, Inc. 5
Strata Dermatology Markets Addressed Psoriasis Eczema (Atopic Derm.) Vitiligo Acne 6 Psoriasis
Treatment Market* Size (2019 to 2027)2019 Global Market Value of $20.1B USD 1Projected Market Value of $40.6B USD by 2027 1CAGR of 9.2% 2020-2027 1 Eczema Treatment Market* Size (2020 to 2026)2020 Global Market Value of $11.8B USD2Projected
Market Value of $21.8B USD by 20262CAGR of 13.1% 2021-20262 1 Fortune Business Insights Market Report 2019; 2016-2018 historical, 2019 base year, 2020-2027 projected2 Market Data Forecast Analysis Report 2020; 2020 base year, 2021-2026
projected 3 Fortune Business Insights Market Report 2018; 2015-2017 historical, 2018 base year, 2019-2026 projected* Treatment market(s) include Rx drug therapies Vitiligo Treatment Market* Size (2018 to 2026)2018 Global Market Value of $1.2B
USD3Projected Market Value of $1.9B USD by 20263CAGR of 5.8% 2019-20263 Acne Treatment Market* Size (2019 to 2027)2019 Global Market Value of $7.7B USD3Projected Market Value of $11.1B USD by 20273CAGR of 4.6% 2020-20273
Growing Demand for Drug-Free Treatment Options 7 Source: Dermatology Devices Report, Grand View
Research 2021 Base year 2020, historic information 2016 to 2019, and forecast 2021 to 2028 USD Millions USD Millions $7.1B $34.1B $5.1B $993M Projected CAGR +21.2%2021-2028 Projected CAGR +19.9%2021-2028
XTRAC® Treatments by Indication – United States 8 5% 80% 15% Opportunities exist for expanding use
for other approved indicationsVitiligo Eczema (Atopic Dermatitis) #1use for XTRAC® lasers domestically Psoriasis treatments remain
Treatment Options Addressing Psoriasis Indication6 9 XTRAC NB-UVB* Topical
Steroids Non-biologic Systemics Biologics Approximate Costs ($) Cost competitive 1K-3K 3K-9K 1K -7K 1K 32K-68K Clinical Impact Better clinical outcomes (PASI%75) 92% 71% 75% 48% 50-70% Speed of Onset (in weeks) Very fast
rate of response 5 10 3 14 12 Days of Actual Care Least days of actual care 18 80 294 52 12-65 Remission Remission without maintenance 2.5 months Continued withmaintenance Continued withmaintenance Continued
withmaintenance Continued withmaintenance Adverse Events Least significant side effects MildTemp MildTemp Mild-ModTemp-Lasting Mild-SevereTemp-Lasting Mild-SevereTemp-Lasting *Narrow band UVB Light Therapy
Best-in-class Excimer TREATMENT XTRAC® is the Leader in Targeted 308nm Excimer Laser Therapy
10 Safe & Effective Treatment 150+ Peer-reviewed clinical studies Economical for patients and payors Win-Win for providers and their patients
Growing Installed Base Drives Recurring Revenue Model 11 01/01/19 Systems
12/31/19 1/01/20 12/31/20 Systems 12/31/21 01/01/21 Systems Net Installed Base Growth 2019-2021 27% growth in installed base over the last 3 years Actively redeploying under utilized devices Group and international placements help
drive growth +160 -76 +106 -76 +169 -82 +84 net +30 net +87 net
A True Partnership – Delivering a Complete Business Solution 12 Clinical Support Reimbursement
Support Call Center Support Field Service Support Consumables and Parts Laser Upgrades Co-pay Assistance DTC Marketing
Partner Academic Institutions 13
Key Priority: Driving Commercial Execution 14 Sustain investment in DTC marketing Continue
to focus and grow high-volume accounts Drive increased utilization across all indications Increase marketing to drive awareness among derms Historical trends show positive correlation between DTC investment and revenue growth High-volume
accounts in Q4, 2021 accounted for 54% of recurring revenues Expand usage for all approved indications beyond psoriasis to further drive revenue growth opportunities with existing partners Direct to Derm marketing – Increasing clinical data
to support all indications and reinforce safety, efficacy and cost benefit to patients and clinics
Domestic Installed Base Growth Drivers 832 1,962 251* XTRAC Partners Group Clinics As of
12/31/20 As of 12/31/19 1,962 clinics owned by 49 roll-up groups at 12/30/2020251 (13%) of which are XTRAC partners at 12/30/2020Signed strategic expansion agreements with major groupsIncreased from 251 at 12/30/2020 to 310 at
9/30/2021 Expansion into group clinic roll ups 300-400 clinics own Excimer lasers Conversion to XTRAC partnership leads to immediate revenue15 Comebacks in 2018 (4 in 2017)19 Comebacks in 201923 Comebacks in 202048 Comebacks
2021 Comebacks 15 * Combination of new XTRAC placements and Clinic acquisitions 820 1,673 221* 746 1,200 86* As of 12/31/18 XTRAC® Growth in Groups
Domestic Market: Installed Base – Sales and Service Engine Overview890 Partner XTRAC® Clinics200+ Sold
XTRAC4 Regions30 Sales Territories2 National Account Managers15 Field Service TechsIn-House Call Center to Qualify LeadsPredominant Provider of Excimer Laser Treatments 16 Territories color coded
International Market: Installed Base Strategic Growth TargetsCurrent Markets: China, Japan, Saudi
Arabia, S. KoreaRecent approval in IsraelInsurance covered in most marketsUsage per device higher than domestic market1,300 OUS devices sold and in servicePlacement recurring revenue model agreements:Executed for South Korea (July 2019)Executed
for Japan (October 2020)Executed for China (January 2021)54 International partner XTRAC® clinics (up from 28 in
2020) 17
Integration of the U.S. Pharos Dermatology Business of Ra Medical Systems 18 250+ Pharos
service contract holders contacted by XTRAC® representative to discuss options going forward74 service calls made by STRATA field service technicians since close13 Pharos users transitioned to XTRAC® in first 6 weeksAdditional Pharos 17
conversions in Q4 2021, in line with expectationsPharos business anticipated to be accretive in Q1, 2022
Recent Acquisition of Novel Acne Treatment 19
Theraclear Acquisition 20 Substantially broadens STRATA’s opportunity with expansion potential into
the estimated $5.5 billion acne care market Leverages STRATA’s innovative marketing platform, commercial team and worldwide distributor network to drive additional revenue growth Creates a robust pipeline of new opportunities to target
dermatologic conditions beyond acne with a unique light treatment approach Reinforces STRATA’s vision to be the premier provider of medical devices to dermatology community
Commercial Drivers in 2022 21 Continue DTC advertising campaign with social media XTRAC® Awareness:
Co-Op advertising to suitable patients (digital + print) Develop patient advocacy partnerships Broadened commercial strategy to expand use within partner practices Added emphasis on professional relations and clinical
communications Sponsorship of select dermatology conferences and trade shows Insurance coverage gap analysis and activity (vitiligo, atopic dermatitis) Sales force training and execution Grow installed base and redeploy under-utilized
devices Continue transition and integration of Ra Medical’s Pharos customers Launch new acne device based on acquired technology from Theravant
Fourth Quarter and Full Year 2021 Financial Highlights 22 Fourth Quarter and Full Year 2021 Financial
HighlightsPreliminary, unaudited total revenue is expected to range from $8.8 million to $9.2 million, compared to $6.7 million in the fourth quarter of 2020Preliminary, unaudited total revenue for the full year 2021 is expected to range from
$29.7 million to $30.1 million, compared to $23.1 million for the full year 2020Cash and cash equivalents, including restricted cash was $12.5 million as of December 31, 2021, as compared to $18.1 million as of December 31, 2020Fourth Quarter
2021 Operational HighlightsPlaced 34 domestic XTRAC systems, resulting in net systems placed in U.S. dermatologists’ offices of 890, of which 18 are comebacks from previous excimer device owners Increased international partner XTRAC clinics to
54, up from 28 in 2020 and 10 in 2019Converted 17 Pharos systems acquired from Ra Medical’s U.S. dermatology business to STRATA’s recurring revenue model
Financial Metrics 23 * Total recurring revenue over total installed base** Company estimates not
provided Unaudited quarterly results * See press release dated November 10, 2021 for definitions of non-GAAP measures 2018 Q1 '19 Q2 '19 Q3 '19 Q4 '19 2019 Q1 '20 Q2 '20 Q3 '20 Q4 '20 2020 Q1 '21 Q2'21 Q3'21 Dermatology
recurring revenue $21,053 $5,312 $5,839 $5,991 $6,571 $23,713 $5,701 $2,796 $3,835 $5,077 $17,409 $4,679 $5,452 $5,710 Dermatology equipment revenue 8,802 2,171 1,886 1,489 2,327 7,873 1,029 1,234
1,778 1,640 5,681 1,148 1,930 2,001 Total revenue $29,855 $7,483 $7,725 $7,480 $8,898 $31,586 $6,730 $4,030 $5,613 $6,717 $23,090 $5,827 $7,382 $7,711 Domestic partner installed base 746 754 764
784 820 820 822 789 813 832 832 837 848 880 International installed base 0 0 0 2 10 12 16 17 24 28 28 34 41 49 Average recurring revenue/device*
$7,055 $7,045 $7,643 $7,622 $7,917 $7,571 $6,803 $3,469 $4,582 $5,903 $5,145 $5,372 $6,133 $6,146 Dermatology recurring revenue margin 65% 66% 70% 67% 77% 70% 68% 51% 64% 74% 67% 68% 70% 74% Total Company
margin 57% 62% 64% 62% 74% 64% 65% 49% 58% 68% 61% 64% 65% 70%
STRATA Key Investment Takeaways 24 Differentiated Treatment providing a Win-Win-Win for Patients
+ Clinics + Payers Addressing Large and Growing Markets +Positioned for Inorganic Growth Proven Business Model to Expand + Achieve Sustainable Results and Shareholder Returns
Investor Presentation December
2020 Thank
You
Investor Presentation December
2020 Appendix
Board of Directors William Humphries Chairman of the Board andGovernance & Compensation
Committee CEO, Isosceles Pharmaceuticals, Inc. former President & Group Chairman Ortho Dermatologics, Merz Pharmaceuticals, , Stiefel Pharmaceuticals, , Allergan Pharmaceuticals Dr. Uri Geiger CEO Accelmed Inc. CEO Exalenz Bioscience,
GalayOr Networks Nachum ShamirGovernance & Compensation Committee Chairman and Audit Committee Chairman & CEO Luminex Corporation, CEO Given Imaging Samuel RubinsteinAudit Committee and Governance & Compensation
Committee Chairman of Board Trima Pharmaceuticals, former CEO & General Manager Taro Pharmaceuticals, Inc. Douglas StrangAudit Committee Chairman Former partner PWC, Head of Global Pharmaceuticals & Life Science Advisory, US
Pharmaceutical & Life Science LeaderAudit Chairman Robert J. MocciaPresident & CEO CEO STRATA Skin Sciences, CEO Encore Dermatology, Inc. CEO Precision Dermatology, Inc. 27
Multicenter Psoriasis Study7 124 patients were enrolled and 80 completed the protocol. 72% achieved at
least 75% clearing in an average of 6.2 treatments. 84% of patients reached improvement of 75% or better after 10 or fewer treatments. 50% of patients reached improvement of 90% or better after 10 or fewer treatments. Common side effects
included erythema, blisters, hyperpigmentation, and erosions, but were well tolerated. Scalp Study9 All patients improved. 17/35 (49%) of patients cleared >95% (mean: 21 treatments; range: 6-52) and 16/35 (45%) cleared 50-95%.
Conclusion – The excimer laser is a successful approach to treatment of psoriasis of the scalp, being a simple treatment that can be performed in a short period of time with a high rate of effectiveness. Sample Studies From 150+ Clinical
Studies Vitiligo Study8 Out of 221 vitiligo patches treated, 50.6% showed 75% pigmentation or more, 25.5% achieved 100% pigmentation of their patches, and 64.3% showed 50% pigmentation or more. Lesions on the face responded better than
lesions elsewhere. Conclusion: The 308-nm xenon chloride excimer laser is an effective and safe modality for the treatment of vitiligo, with good results achieved in a relatively short duration of time. Pediatric Study10 4 children with a
mean age of 11.0 years and 12 adults with a mean age of 48.8 years completed the protocol. Both the children and the adult groups yielded a significant decrease in psoriatic severity scores of their respective target lesions. The children’s
group had a greater reduction (91.3% reduction) as compared to the adult treatment group (61.6% reduction). 28
29 After 4 tx After 2 tx Baseline Clinical Protocol – 6.2 treatments to PASI 75 Beam of UVB
light applied to the affected area PASI – A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis XTRAC®The treatment for
Psoriasis Promotes immunosuppression UVB light induces apoptosis of the keratinocytes and T cells in the dermis Induces alterations in cytokine profile XTRAC®: Psoriasis
XTRAC®: Vitiligo 30 Beam of UVB light applied to the affected area XTRAC®The solution for
Vitiligo Results in re-pigmentation UVB light reduces the immune system’s attack on the melanocytes Simple, safe, effective + long-lastingExcimer laser Baseline After 18 tx After 29 tx